Journal of Translational Medicine (Feb 2021)

Biomarker profiling for risk of future heart failure (HFpEF) development

  • Chris J. Watson,
  • Joe Gallagher,
  • Mark Wilkinson,
  • Adam Russell-Hallinan,
  • Isaac Tea,
  • Stephanie James,
  • James O’Reilly,
  • Eoin O’Connell,
  • Shuaiwei Zhou,
  • Mark Ledwidge,
  • Ken McDonald

DOI
https://doi.org/10.1186/s12967-021-02735-3
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background The purpose of this study was to investigate the utility of BNP, hsTroponin-I, interleukin-6, sST2, and galectin-3 in predicting the future development of new onset heart failure with preserved ejection fraction (HFpEF) in asymptomatic patients at-risk for HF. Methods This is a retrospective analysis of the longitudinal STOP-HF study of thirty patients who developed HFpEF matched to a cohort that did not develop HFpEF (n = 60) over a similar time period. Biomarker candidates were quantified at two time points prior to initial HFpEF diagnosis. Results HsTroponin-I and BNP at baseline and follow-up were statistically significant predictors of future new onset HFpEF, as was galectin-3 at follow-up and concentration change over time. Interleukin-6 and sST2 were not predictive of future development of new onset HFpEF in this study. Unadjusted biomarker combinations of hsTroponin-I, BNP, and galectin-3 could significantly predict future HFpEF using both baseline (AUC 0.82 [0.73,0.92]) and follow-up data (AUC 0.86 [0.79,0.94]). A relative-risk matrix was developed to categorize the relative-risk of new onset of HFpEF based on biomarker threshold levels. Conclusion We provided evidence for the utility of BNP, hsTroponin-I, and Galectin-3 in the prediction of future HFpEF in asymptomatic event-free populations with cardiovascular disease risk factors.

Keywords